42 results on '"Shi, Zhumei"'
Search Results
2. Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas
- Author
-
Yin, Jianxing, Wang, Xiefeng, Ge, Xin, Ding, Fangshu, Shi, Zhumei, Ge, Zehe, Huang, Guang, Zhao, Ningwei, Chen, Dongyin, Zhang, Junxia, Agnihotri, Sameer, Cao, Yuandong, Ji, Jing, Lin, Fan, Wang, Qianghu, Zhou, Qigang, Wang, Xiuxing, You, Yongping, Lu, Zhimin, and Qian, Xu
- Published
- 2023
- Full Text
- View/download PDF
3. Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation
- Author
-
Ge, Zehe, Xu, Miao, Ge, Yuqian, Huang, Guang, Chen, Dongyin, Ye, Xiuquan, Xiao, Yibei, Zhu, Hongyu, Yin, Rong, Shen, Hua, Ma, Gaoxiang, Qi, Lianwen, Wei, Guining, Li, Dongmei, Wei, Shaofeng, Zhu, Meng, Ma, Hongxia, Shi, Zhumei, Wang, Xiuxing, Ge, Xin, and Qian, Xu
- Published
- 2023
- Full Text
- View/download PDF
4. METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling
- Author
-
Yin, Jianxing, Ding, Fangshu, Cheng, Zhangchun, Ge, Xin, Li, Yanhui, Zeng, Ailiang, Zhang, Junxia, Yan, Wei, Shi, Zhumei, Qian, Xu, You, Yongping, Ding, Zhiliang, Ji, Jing, and Wang, Xiefeng
- Published
- 2023
- Full Text
- View/download PDF
5. Reactivating PTEN to impair glioma stem cells by inhibiting cytosolic iron-sulfur assembly.
- Author
-
Yin, Jianxing, Ge, Xin, Ding, Fangshu, He, Liuguijie, Song, Keying, Shi, Zhumei, Ge, Zehe, Zhang, Junxia, Ji, Jing, Wang, Xiefeng, Zhao, Ningwei, Shu, Chuanjun, Lin, Fan, Wang, Qianghu, Zhou, Qigang, Cao, Yuandong, Liu, Wentao, Ye, Dan, Rich, Jeremy N., and Wang, Xiuxing
- Subjects
GLIOMAS ,STEM cells ,METHYLGUANINE ,BRAIN tumors ,DRUGS ,GLIOBLASTOMA multiforme - Abstract
Glioblastoma, the most lethal primary brain tumor, harbors glioma stem cells (GSCs) that not only initiate and maintain malignant phenotypes but also enhance therapeutic resistance. Although frequently mutated in glioblastomas, the function and regulation of PTEN in PTEN-intact GSCs are unknown. Here, we found that PTEN directly interacted with MMS19 and competitively disrupted MMS19-based cytosolic iron-sulfur (Fe-S) cluster assembly (CIA) machinery in differentiated glioma cells. PTEN was specifically succinated at cysteine (C) 211 in GSCs compared with matched differentiated glioma cells. Isotope tracing coupled with mass spectrometry analysis confirmed that fumarate, generated by adenylosuccinate lyase (ADSL) in the de novo purine synthesis pathway that is highly activated in GSCs, promoted PTEN C211 succination. This modification abrogated the interaction between PTEN and MMS19, reactivating the CIA machinery pathway in GSCs. Functionally, inhibiting PTEN C211 succination by reexpressing a PTEN C211S mutant, depleting ADSL by shRNAs, or consuming fumarate by the US Food and Drug Administration–approved prescription drug N-acetylcysteine (NAC) impaired GSC maintenance. Reexpressing PTEN C211S or treating with NAC sensitized GSC-derived brain tumors to temozolomide and irradiation, the standard-of-care treatments for patients with glioblastoma, by slowing CIA machinery–mediated DNA damage repair. These findings reveal an immediately practicable strategy to target GSCs to treat glioblastoma by combination therapy with repurposed NAC. Editor's summary: Glioma stem cells promote glioblastoma growth and therapy resistance but are hard to target. Yin et al. report that posttranslational succination of PTEN at residue 211 (cysteine) promotes glioma stem cell maintenance by reactivating cytosolic iron-sulfur cluster assembly formation. This PTEN succination was driven by purine biosynthesis–derived fumarate. Administration of N-acetylcysteine to deplete the fumarate sensitized xenografted tumors in mice to both standard-of-care temozolomide and irradiation, indicating potential translational relevance for this difficult-to-treat cancer. —Catherine Charneski [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
- Author
-
Nie, Er, Miao, Faan, Jin, Xin, Wu, Weining, Zhou, Xu, Zeng, Ailiang, Yu, Tianfu, Zhi, Tongle, Shi, Zhumei, Wang, Yingyi, Zhang, Junxia, Liu, Ning, and You, Yongping
- Published
- 2019
- Full Text
- View/download PDF
7. MiR-181b suppress glioblastoma multiforme growth through inhibition of SP1-mediated glucose metabolism
- Author
-
Yin, JianXing, Shi, ZhuMei, Wei, WenJin, Lu, Chenfei, Wei, Yutian, Yan, Wei, Li, Rui, Zhang, JunXia, You, YongPing, and Wang, XieFeng
- Published
- 2020
- Full Text
- View/download PDF
8. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma
- Author
-
Lu, Chenfei, Wei, Yutian, Wang, Xiefeng, Zhang, Zhuoran, Yin, Jianxing, Li, Wentao, Chen, Lijiu, Lyu, Xiao, Shi, Zhumei, Yan, Wei, and You, Yongping
- Published
- 2020
- Full Text
- View/download PDF
9. Sterol regulatory element-binding protein 2 maintains glioblastoma stem cells by keeping the balance between cholesterol biosynthesis and uptake.
- Author
-
Gu, Danling, Zhou, Fengqi, You, Hao, Gao, Jiancheng, Kang, Tao, Dixit, Deobrat, Wu, Qiulian, Yang, Kailin, Ci, Shusheng, Shan, Danyang, Fan, Xiao, Yuan, Wei, Zhang, Qian, Lu, Chenfei, Li, Daqi, Zhao, Ningwei, Shi, Zhumei, Gao, Wei, Lin, Fan, and Man, Jianghong
- Published
- 2023
- Full Text
- View/download PDF
10. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis
- Author
-
Ge, Xin, Pan, Min-Hong, Wang, Lin, Li, Wei, Jiang, Chengfei, He, Jun, Abouzid, Khaled, Liu, Ling-Zhi, Shi, Zhumei, and Jiang, Bing-Hua
- Published
- 2018
- Full Text
- View/download PDF
11. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor
- Author
-
Chen, Yunxiang, Li, Rui, Pan, Minhong, Shi, Zhumei, Yan, Wei, Liu, Ning, You, Yongping, Zhang, Junxia, and Wang, Xiefeng
- Published
- 2017
- Full Text
- View/download PDF
12. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT
- Author
-
Nie, Er, Jin, Xin, Wu, Weining, Yu, Tianfu, Zhou, Xu, Shi, Zhumei, Zhang, Junxia, Liu, Ning, and You, Yongping
- Published
- 2017
- Full Text
- View/download PDF
13. Chromium (VI)‐induced ALDH1A1/EGF axis promotes lung cancer progression.
- Author
-
Ge, Xin, Li, Mengdie, Song, Guo‐Xin, Zhang, Zhixiang, Yin, Jianxing, Ge, Zehe, Shi, Zhumei, Liu, Ling‐Zhi, Jiang, Bing‐Hua, Qian, Xu, and Shen, Hua
- Subjects
LUNG cancer ,CANCER invasiveness ,ALDEHYDE dehydrogenase ,CANCER cell growth ,CHROMIUM - Abstract
Cr(VI) is broadly applied in industry. Cr(VI) exposure places a big burden on public health, thereby increasing the risk of lung squamous cell carcinoma (LUSC). The mechanisms underlying Cr(VI)‐induced LUSC remain largely elusive. Here, we report that the cancer stem cell (CSC)/tumour‐initiating cell (TIC)‐like subgroup within Cr(VI)‐transformed bronchial epithelial cells (CrT) promotes lung cancer tumourigenesis. Mechanistically, Cr(VI) exposure specifically increases the expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1), a CSC marker, through KLF4‐mediated transcription. ALDH1A1 maintains self‐renewal of CrT/TICs and facilitates the expression and secretion of EGF from CrT/TICs, which subsequently promotes the activation of EGFR signalling in differentiated cancer cells and tumour growth of LUSC. In addition, the ALDH1A1 inhibitor A37 and gemcitabine synergistically suppress LUSC progression. Importantly, high ALDH1A1 expression levels are positively correlated with advanced clinical stages and predict poor survival in LUSC patients. These findings elucidate how ALDH1A1 modulates EGF secretion from TICs to facilitate LUSC tumourigenesis, highlighting new therapeutic strategies for malignant lung cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. HDAC2- and EZH2-Mediated Histone Modifications Induce PDK1 Expression through miR-148a Downregulation in Breast Cancer Progression and Adriamycin Resistance.
- Author
-
Xie, Yunxia, Shi, Zhumei, Qian, Yingchen, Jiang, Chengfei, Liu, Wenjing, Liu, Bingjie, and Jiang, Binghua
- Subjects
- *
DISEASE progression , *REVERSE transcriptase polymerase chain reaction , *DOXORUBICIN , *WESTERN immunoblotting , *IMMUNOHISTOCHEMISTRY , *PRECIPITIN tests , *PEARSON correlation (Statistics) , *T-test (Statistics) , *EPITHELIAL-mesenchymal transition , *FLUORESCENT antibody technique , *DESCRIPTIVE statistics , *STATISTICAL hypothesis testing , *CELL lines , *TUMOR markers , *DATA analysis software , *EPIGENOMICS , *BREAST tumors , *DRUG resistance in cancer cells - Abstract
Simple Summary: Epigenetic modification plays an important regulatory role in breast cancer progression. However, the relationship between epigenetic modification with tumor metabolism has not yet been fully elucidated. PDK1, as a key enzyme in glucose metabolism, mediates multiple tumors development. But, the mechanism of epigenetic modification in regulating PDK1 remains unclear in breast cancer. Here, we demonstrated that HDAC2 and EZH2 upregulated PDK1 expression through inhibiting miR-148a. Importantly, miR-148a targeting PDK1 regulated breast cancer cells glycolysis, invasion, epithelial-mesenchymal transition (EMT) and Adriamycin resistance. Our results suggested that the HDAC2/EZH2/miR-148a/PDK1 axis may be a promising potential therapeutic strategy. Background: Breast cancer has one of highest morbidity and mortality rates for women. Abnormalities regarding epigenetics modification and pyruvate dehydrogenase kinase 1 (PDK1)-induced unusual metabolism contribute to breast cancer progression and chemotherapy resistance. However, the role and mechanism of epigenetic change in regulating PDK1 in breast cancer remains to be elucidated. Methods: Gene set enrichment analysis (GSEA) and Pearson's correlation analysis were performed to analyze the relationship between histone deacetylase 2 (HDAC2), enhancer of zeste homologue 2 (EZH2), and PDK1 in database and human breast cancer tissues. Dual luciferase reporters were used to test the regulation between PDK1 and miR-148a. HDAC2 and EZH2 were found to regulate miR-148a expression through Western blotting assays, qRT-PCR and co-immunoprecipitation assays. The effects of PDK1 and miR-148a in breast cancer were investigated by immunofluorescence (IF) assay, Transwell assay and flow cytometry assay. The roles of miR-148a/PDK1 in tumor growth were investigated in vivo. Results: We found that PDK1 expression was upregulated by epigenetic alterations mediated by HDAC2 and EZH2. At the post-transcriptional level, PDK1 was a new direct target of miR-148a and was upregulated in breast cancer cells due to miR-148a suppression. PDK1 overexpression partly reversed the biological function of miR-148a—including miR-148a's ability to increase cell sensitivity to Adriamycin (ADR) treatment—inhibiting cell glycolysis, invasion and epithelial–mesenchymal transition (EMT), and inducing apoptosis and repressing tumor growth. Furthermore, we identified a novel mechanism: DNMT1 directly bound to EZH2 and recruited EZH2 and HDAC2 complexes to the promoter region of miR-148a, leading to miR-148a downregulation. In breast cancer tissues, HDAC2 and EZH2 protein expression levels also were inversely correlated with levels of miR-148a expression. Conclusion: Our study found a new regulatory mechanism in which EZH2 and HDAC2 mediate PDK1 upregulation by silencing miR-148a expression to regulate cancer development and Adriamycin resistance. These new findings suggest that the HDAC2/EZH2/miR-148a/PDK1 axis is a novel mechanism for regulating cancer development and is a potentially promising target for therapeutic options in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Inhibition of vascular endothelial growth factor expression by Chinese medicine of Hedyotis diffusa Willd herbal compounds
- Author
-
Wang, Min, Shi, Zhumei, Liu, Dan, Zhang, Gong-Yu, Sha, Jiahao, and Jiang, Bing-Hua
- Published
- 2010
- Full Text
- View/download PDF
16. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling.
- Author
-
Wei, Yutian, Lu, Chenfei, Zhou, Peng, Zhao, Lin, Lyu, Xiao, Yin, Jianxing, Shi, ZhuMei, and You, Yongping
- Published
- 2021
- Full Text
- View/download PDF
17. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
- Author
-
Nie, Er, Jin, Xin, Miao, Faan, Yu, Tianfu, Zhi, Tongle, Shi, Zhumei, Wang, Yingyi, Zhang, Junxia, Xie, Manyi, and You, Yongping
- Published
- 2021
- Full Text
- View/download PDF
18. Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas.
- Author
-
Shi, Zhumei, Ge, Xin, Li, Mengdie, Yin, Jianxing, Wang, Xiefeng, Zhang, Junxia, Chen, Dongyin, Li, Xinjian, Wang, Xiuxing, Ji, Jing, You, Yongping, and Qian, Xu
- Subjects
- *
METHYLGUANINE - Published
- 2022
- Full Text
- View/download PDF
19. MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
- Author
-
Shi, Zhumei, Chen, Qiudan, Li, Chongyong, Wang, Lin, Qian, Xu, Jiang, Chengfei, Liu, Xue, Wang, Xiefeng, Li, Hai, Kang, Chunsheng, Jiang, Tao, Liu, Ling-Zhi, You, Yongping, Liu, Ning, and Jiang, Bing-Hua
- Published
- 2014
- Full Text
- View/download PDF
20. Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer.
- Author
-
Shen, Hua, Zhu, Fang, Liu, Jinyuan, Xu, Tongpeng, Pei, Dong, Wang, Rong, Qian, Yingying, Li, Qi, Wang, Lin, Shi, Zhumei, Zheng, Jitai, Chen, Qiudan, Jiang, Binghua, and Shu, Yongqian
- Subjects
GEFITINIB ,GENE expression ,SMALL cell lung cancer ,NATURAL immunity ,EPIDERMAL growth factor receptors ,MICRORNA ,PROTEIN kinase B - Abstract
Resistance to TKI treatment is a major obstacle in effective treatment of NSCLC. Besides EGFR mutation status, the mechanisms involved are largely unknown. Some evidence supports a role for microRNA 21 in modulating drug sensitivity of chemotherapy but its role in NSCLC TKI resistance still remains unexplored. This study aimed to investigate whether NSCLC miR-21 mediated resistance to TKIs also results from Pten targeting. Here, we show miR-21 promotes cancer by negatively regulating Pten expression in human NSCLC tissues: high miR-21 expression levels were associated with shorter DFS in 47 NSCLC patients; high miR-21/low Pten expression levels indicated a poor TKI clinical response and shorter overall survival in another 46 NSCLC patients undergoing TKI treatment. In vitro assays showed that miR-21 was up-regulated concomitantly to down-regulation of Pten in pc-9/GR cells in comparison with pc-9 cells. Moreover, over-expression of miR-21 significantly decreased gefitinib sensitivity by down-regulating Pten expression and activating Akt and ERK pathways in pc-9 cells, while miR-21 knockdown dramatically restored gefitinib sensitivity of pc-9/GR cells by up-regulation of Pten expression and inactivation of AKT and ERK pathways, in vivo and in vitro. We propose alteration of miR-21/Pten expression as a novel mechanism for TKI resistance in NSCLC cancer. Our findings provide a new basis for using miR 21/Pten-based therapeutic strategies to reverse gefitinib resistance in NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Association between survivin −31G>C promoter polymorphism and cancer risk: a meta-analysis.
- Author
-
Wang, Xiefeng, Huang, Lili, Xu, Yanjie, Shi, Zhumei, Wang, Yingyi, Zhang, Junxia, Wang, Xirui, Cao, Lei, Luo, Hui, Chen, Jiawei, Liu, Ning, Yin, Yongmei, and You, Yongping
- Subjects
SURVIVIN (Protein) ,GENETIC polymorphisms ,CANCER risk factors ,META-analysis ,DISEASE susceptibility - Abstract
Survivin is an inhibitor of apoptosis protein and has a crucial role in the development of cancer. The survivin −31G>C (rs9904341) promoter polymorphism influences survivin expression and has been implicated in cancer risk. However, conflicting results have been published from studies on the association between survivin −31G>C polymorphism and the risk of cancer. To clarify the role of this polymorphism in cancer, we performed a meta-analysis of all available and relevant published studies, involving a total of 3485 cancer patients and 3964 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results indicated that the variant genotypes were associated with a significantly increased cancer risk (CC vs GG: OR=1.58, 95% CI=1.20-2.10; CC/GC vs GG: OR=1.23, 95% CI=1.00-1.51; CC vs GG/GC: OR=1.51, 95% CI=1.23-1.85). In the stratified analyses, significantly increased risk was associated with the Asian populations (CC vs GG: OR=1.67, 95% CI=1.16-2.40; CC vs GG/GC: OR=1.50, 95% CI=1.17-1.91). We also performed the analyses by cancer type, and no statistical association was observed. The results suggest that the survivin −31G>C promoter polymorphism might be associated with an increased risk of cancer, especially in the Asian populations. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1α expression
- Author
-
Bian, Chuan-Xiu, Shi, Zhumei, Meng, Qiao, Jiang, Yue, Liu, Ling-Zhi, and Jiang, Bing-Hua
- Subjects
- *
REGULATION of neovascularization , *VASCULAR endothelial growth factors , *TRANSCRIPTION factors , *GENE expression , *RNA , *CANCER cell proliferation , *PROTEIN kinases , *PREVENTION ,TUMOR growth prevention - Abstract
Abstract: The 70kDa ribosomal S6 kinase 1 (p70S6K1), a downstream target of phosphoinositide 3-kinase (PI3K) and ERK mitogen-activated protein kinase (MAPK), is an important regulator of cell cycle progression, and cell proliferation. Recent studies indicated an important role of p70S6K1 in PTEN-negative and AKT-overexpressing tumors. However, the mechanism of p70S6K1 in tumor angiogenesis remains to be elucidated. In this study, we specifically inhibited p70S6K1 activity in ovarian cancer cells using vector-based small interfering RNA (siRNA) against p70S6K1. We found that knockdown of p70S6K1 significantly decreased VEGF protein expression and VEGF transcriptional activation through the HIF-1α binding site at its enhancer region. The expression of p70S6K1 siRNA specifically inhibited HIF-1α, but not HIF-1β protein expression. We also found that p70S6K1 down-regulation inhibited ovarian tumor growth and angiogenesis, and decreased cell proliferation and levels of VEGF and HIF-1α expression in tumor tissues. Our results suggest that p70S6K1 is required for tumor growth and angiogenesis through HIF-1α and VEGF expression, providing a molecular mechanism of human ovarian cancer mediated by p70S6K1 signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
23. BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
- Author
-
Nie, Er, Jin, Xin, Wu, Weining, Yu, Tianfu, Zhou, Xu, Zhi, Tongle, Shi, Zhumei, Zhang, Junxia, Liu, Ning, and You, Yongping
- Abstract
The acquisition of drug resistance is a persistent clinical problem limiting the successful treatment of glioblastoma (GBM). However, the molecular mechanisms by which initially chemoresponsive tumors develop therapeutic resistance remain poorly understood. In this study, we report that BACH1, a heme-binding protein that participates in transcriptional repression or activation, was significantly upregulated in glioblastoma tissues. Overexpression of BACH1 in GBM cells conferred resistance to temozolomide, whereas its inhibition markedly sensitized resistant cells to temozolomide in vitro and in vivo. Further investigation revealed that BACH1 activation significantly enhanced the expression of MGMT, and depletion of p53 disrupted the effects of BACH1 on MGMT and temozolomide resistance. P53 sequesters SP1 to prevent its binding to the MGMT promoter region and thus inhibits MGMT expression. Moreover, BACH1 overexpression impaired the association between p53 and SP1 via competitive binding p53, and antagonized the impact of p53 on MGMT expression. Finally, we found that BACH1 low expression correlated with better prognosis in GBM patients undergoing temozolomide therapy, especially in patients with wild-type TP53. Collectively, our findings identify a potential mechanism by which wild-type TP53 GBM cells develop resistance to temozolomide and suggest that targeting this pathway may be beneficial for overcoming resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Diallyl trisulfide sensitizes radiation therapy on glioblastoma through directly targeting thioredoxin 1.
- Author
-
Tian, Yangyang, Ge, Zehe, Xu, Miao, Ge, Xin, Zhao, Mengjie, Ding, Fangshu, Yin, Jianxing, Wang, Xiuxing, You, Yongping, Shi, Zhumei, and Qian, Xu
- Subjects
- *
THIOREDOXIN , *MICHAEL reaction , *METHYLGUANINE , *GLIOBLASTOMA multiforme , *RADIOTHERAPY , *REACTIVE oxygen species - Abstract
Radiotherapy is a standard-of-care treatment approach for glioblastoma (GBM) patients, but therapeutic resistance to radiotherapy remains a major challenge. Here we demonstrate that diallyl trisulfide (DATS) directly conjugates with cysteine (C) 32 and C35 (C32/35) residues of thioredoxin 1 (Trx1) through Michael addition reactions. Due to localizing in activity center of Trx1, the conjugation between DATS and C32/35 results in inhibition of Trx1 activity, therefore disturbing thioredoxin system and leading to accumulated levels of reactive oxygen species (ROS). High levels of Trx1 expression are correlated with poor prognosis of glioma patients. Notably, we reveal that DATS synergistically enhances irradiation (IR)-induced ROS accumulation, apoptosis, DNA damage, as well as inhibition of tumor growth of GBM cells. These findings highlight the potential benefits of DATS in sensitizing radiotherapy of GBM patients. [Display omitted] • Thioredoxin 1 (Trx1) was identified as the direct target of Diallyl trisulfide (DATS). • DATS conjugates with C32/35 residues of Trx1 through Michael addition reactions. • The conjugation of DATS with Trx1 inhibited Trx1 activity and disturbed redox balance. • DATS synergistically enhanced the radiotherapy effects of GBM cells. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. KDM3A Senses Oxygen Availability to Regulate PGC-1α-Mediated Mitochondrial Biogenesis.
- Author
-
Qian, Xu, Li, Xinjian, Shi, Zhumei, Bai, Xiaoming, Xia, Yan, Zheng, Yanhua, Xu, Daqian, Chen, Feng, You, Yongping, Fang, Jing, Hu, Zhibin, Zhou, Qin, and Lu, Zhimin
- Subjects
- *
PEROXISOME proliferator-activated receptors , *OXYGEN detectors , *REACTIVE oxygen species , *NEURAL development , *NUCLEAR receptors (Biochemistry) , *OXYGEN , *OXYGEN carriers - Abstract
Hypoxia, which occurs during tumor growth, triggers complex adaptive responses in which peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) plays a critical role in mitochondrial biogenesis and oxidative metabolism. However, how PGC-1α is regulated in response to oxygen availability remains unclear. We demonstrated that lysine demethylase 3A (KDM3A) binds to PGC-1α and demethylates monomethylated lysine (K) 224 of PGC-1α under normoxic conditions. Hypoxic stimulation inhibits KDM3A, which has a high K M of oxygen for its activity, and enhances PGC-1α K224 monomethylation. This modification decreases PGC-1α's activity required for NRF1- and NRF2-dependent transcriptional regulation of TFAM , TFB1M , and TFB2M , resulting in reduced mitochondrial biogenesis. Expression of PGC-1α K224R mutant significantly increases mitochondrial biogenesis, reactive oxygen species (ROS) production, and tumor cell apoptosis under hypoxia and inhibits brain tumor growth in mice. This study revealed that PGC-1α monomethylation, which is dependent on oxygen availability-regulated KDM3A, plays a critical role in the regulation of mitochondrial biogenesis. • Hypoxia suppresses mitochondrial biogenesis of tumor cells • PGC-1α's activity is inhibited by K224 monomethylation under hypoxic conditions • KDM3A senses oxygen availability for its activity and demethylates PGC-1α • PGC-1α monomethylation reduces hypoxia-induced ROS and apoptosis for tumor growth Qian et al. demonstrated that KDM3A functions as an oxygen sensor and demethylates K224-monomethylated PGC-1α under normoxic conditions. Hypoxia inhibits KDM3A activity and increases PGC-1α K224 monomethylation, resulting in the inhibition of PGC-1α and PGC-1α-dependent mitochondrial biogenesis, a decrease of ROS levels and apoptosis, and the promotion of brain tumor development. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1.
- Author
-
Qian, Xu, Li, Xinjian, Shi, Zhumei, Xia, Yan, Cai, Qingsong, Xu, Daqian, Tan, Lin, Du, Linyong, Zheng, Yanhua, Zhao, Dan, Zhang, Chuanbao, Lorenzi, Philip L., You, Yongping, Jiang, Bing-Hua, Jiang, Tao, Li, Haitao, and Lu, Zhimin
- Subjects
- *
GLYCOLYSIS , *PHOSPHOPROTEIN phosphatases , *PHOSPHOGLYCERATE kinase , *PTEN protein , *PROTEIN kinases , *MITOGEN-activated protein kinase phosphatases - Abstract
The PTEN tumor suppressor is frequently mutated or deleted in cancer and regulates glucose metabolism through the PI3K-AKT pathway. However, whether PTEN directly regulates glycolysis in tumor cells is unclear. We demonstrate here that PTEN directly interacts with phosphoglycerate kinase 1 (PGK1). PGK1 functions not only as a glycolytic enzyme but also as a protein kinase intermolecularly autophosphorylating itself at Y324 for activation. The protein phosphatase activity of PTEN dephosphorylates and inhibits autophosphorylated PGK1, thereby inhibiting glycolysis, ATP production, and brain tumor cell proliferation. In addition, knockin expression of a PGK1 Y324F mutant inhibits brain tumor formation. Analyses of human glioblastoma specimens reveals that PGK1 Y324 phosphorylation levels inversely correlate with PTEN expression status and are positively associated with poor prognosis in glioblastoma patients. This work highlights the instrumental role of PGK1 autophosphorylation in its activation and PTEN protein phosphatase activity in governing glycolysis and tumorigenesis. • PGK1, functioning as a protein kinase, autophosphorylates itself at Y324 • PGK1 autophosphorylation enhances its glycolytic activity via promoting ATP release • PTEN, functioning as a protein phosphatase, dephosphorylates PGK1 pY324 • PGK1 Y324 autophosphorylation promotes brain tumor formation Qian et al. demonstrate that PGK1 functions as a protein kinase and autophosphorylates itself at Y324, leading to subsequent PGK1 activation. This phosphorylation is dephosphorylated by the protein phosphatase activity of PTEN. Loss of PTEN expression in tumors enhances PGK1 activity, thereby promoting glycolysis and brain tumor growth. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.
- Author
-
Shen, Hua, Shen, Jianxin, Wang, Lin, Shi, Zhumei, Wang, Min, Jiang, Bing-hua, and Shu, Yongqian
- Subjects
- *
NON-small-cell lung carcinoma , *MICRORNA genetics , *GENE expression , *TUMOR markers , *DRUG resistance in cancer cells , *CANCER relapse , *CARCINOGENESIS , *PROGNOSIS - Abstract
Non-small cell lung cancer (NSCLC) is the first cause of cancer related death in the world. Biomarkers to predict the relapse and drug resistance could be extremely useful for a clinical doctor to monitor high risk patients and select rational regimen. miRNAs play an important role in lung cancer and detection samples are relatively easy to be obtained, miRNAs could become a promising means of comprehending the oncogenesis and pathogenesis of lung cancer. This study aimed to investigate the function of miR-145 to work as a biomarker in NSCLC. miR-145 expression level in 48 NSCLC tumor tissues and their matched normal tissues were detected by qRT-PCR. miR-145 in 18 paraffin-embedded samples underwent chemotherapy and were assessed by in situ hybridization (ISH). Here we show that miR-145 was down-regulated in NSCLC tissues; down-regulation of miR-145 was correlated with late clinical stage and poorly differentiated carcinoma, and, low expression level of miR-145 could also predict chemotherapy resistance and shorter disease-free survival (DFS). These findings indicated that miR-145 expression may be a useful prognostic marker that could be used for predicting poor differentiation, chemo-resistance and shore DFS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.
- Author
-
Ge, Xin, Li, Mengdie, Yin, Jianxing, Shi, Zhumei, Fu, Yao, Zhao, Ningwei, Chen, Hongshan, Meng, Longxiyu, Li, Xinjian, Hu, Zhibin, Zhao, Xiaozhi, Guo, Hongqian, and Qian, Xu
- Subjects
- *
RENAL cell carcinoma , *PI3K/AKT pathway , *NEOPLASTIC cell transformation , *SUNITINIB , *POST-translational modification - Abstract
Fumarate is an oncometabolite. However, the mechanism underlying fumarate-exerted tumorigenesis remains unclear. Here, utilizing human type2 papillary renal cell carcinoma (PRCC2) as a model, we show that fumarate accumulates in cells deficient in fumarate hydratase (FH) and inhibits PTEN to activate PI3K/AKT signaling. Mechanistically, fumarate directly reacts with PTEN at cysteine 211 (C211) to form S-(2-succino)-cysteine. Succinated C211 occludes tethering of PTEN with the cellular membrane, thereby diminishing its inhibitory effect on the PI3K/AKT pathway. Functionally, re-expressing wild-type FH or PTEN C211S phenocopies an AKT inhibitor in suppressing tumor growth and sensitizing PRCC2 to sunitinib. Analysis of clinical specimens indicates that PTEN C211 succination levels are positively correlated with AKT activation in PRCC2. Collectively, these findings elucidate a non-metabolic, oncogenic role of fumarate in PRCC2 via direct post-translational modification of PTEN and further reveal potential stratification strategies for patients with FH loss by combinatorial AKTi and sunitinib therapy. [Display omitted] • Fumarate directly targets and succinates PTEN at C211 • C211 succination abrogates the interaction of PTEN with the cellular membrane • PTEN C211 succination is positively correlated with PI3K/AKT activation in PRCC2 • Inhibiting PTEN C211 succination or AKT sensitizes PRCC2 to sunitinib treatment Ge et al. report that fumarate, an oncometabolite, succinates PTEN at C211, which abrogates the binding of PTEN with the cellular membrane. C211 succination of PTEN thereby activates PI3K/AKT signaling and promotes tumor growth of PRCC2. Inhibiting PTEN C211 succination or AKT activation enhances sensitivity of PRCC2 to sunitinib treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
- Author
-
Shen, Hua, Liu, Jinyuan, Wang, Rong, Qian, Xu, Xu, Ruitong, Xu, Tongpeng, Li, Qi, Wang, Lin, Shi, Zhumei, Zheng, Jitai, Chen, Qiudan, and Shu, Yongqian
- Subjects
- *
ESTRADIOL , *GEFITINIB , *LUNG cancer treatment , *CANCER cells , *GENETIC regulation , *GENE expression , *EPIDERMAL growth factor receptors , *GENETIC mutation , *THERAPEUTICS - Abstract
Abstract: Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. However, these patients eventually develop resistance to EGFR-TKIs. About 50% of this acquired resistance may be the result of a secondary mutation in the EGFR gene, such as the one corresponding to T790M. In our previous study, we found that combined treatment with fulvestrant and gefitinib decreases the proliferation of H1975 NSCLC cells, compared to treatment with either fulvestrant or gefitinib alone; however, the molecular mechanism for the improved effects of the combination treatment are still unknown. In this study, we confirmed that fulvestrant increases the gefitinib sensitivity of H1975 cells and found that let-7c was most upregulated in the fulvestrant-treated cells. Our data revealed that let-7c increases gefitinib sensitivity by repressing RAS and inactivating the phosphoinositide 3-kinase (PI3K)/AKT and mitogen-activated extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathways. Taken together, our findings suggest that let-7c plays an important role in fulvestrant-induced upregulation of gefitinib sensitivity in H1975 cells. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
30. SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells.
- Author
-
Li M, Zhang Z, He L, Wang X, Yin J, Wang X, You Y, Qian X, Ge X, and Shi Z
- Abstract
Background: The high fatality rate of glioblastoma (GBM) is attributed to glioblastoma stem cells (GSCs), which exhibit heterogeneity and therapeutic resistance. Metabolic plasticity of mitochondria is the hallmark of GSCs. Targeting mitochondrial biogenesis of GSCs is crucial for improving clinical prognosis in GBM patients., Methods: SMYD2-induced PGC1α methylation and followed nuclear export is confirmed by co-immunoprecipitation, cellular fractionation, and immunofluorescence. The effects of SMYD2/PGC1α/CRM1 axis on GSCs mitochondrial biogenesis is validated by OCR, ECAR and intracranial glioma model., Results: PGC1α methylation causes disabled mitochondrial function to maintain the stemness, thereby enhancing radio-resistance of GSCs. SMYD2 drives PGC1α K224 methylation (K224me), which is essential for promoting the stem-like characteristics of GSCs. PGC1α K224me is preferred binding with CRM1, accelerating PGC1α nuclear export and subsequent dysfunction. Targeting PGC1α methylation exhibits significant radiotherapeutic efficacy and prolongs patient survival., Conclusions: These findings unveil a novel regulatory pathway involving mitochondria that governs stemness in GSCs, thereby emphasizing promising therapeutic strategies targeting PGC1α and mitochondria for the treatment of GBM., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
31. HSP90B1-mediated plasma membrane localization of GLUT1 promotes radioresistance of glioblastomas.
- Author
-
Li Y, Ge Y, Zhao M, Ding F, Wang X, Shi Z, Ge X, Wang X, and Qian X
- Abstract
Ionizing radiation is a popular and effective treatment option for glioblastoma (GBM). However, resistance to radiation therapy inevitably occurs during treatment. It is urgent to investigate the mechanisms of radioresistance in GBM and to find ways to improve radiosensitivity. Here, we found that heat shock protein 90 beta family member 1 (HSP90B1) was significantly upregulated in radioresistant GBM cell lines. More importantly, HSP90B1 promoted the localization of glucose transporter type 1, a key rate-limiting factor of glycolysis, on the plasma membrane, which in turn enhanced glycolytic activity and subsequently tumor growth and radioresistance of GBM cells. These findings imply that targeting HSP90B1 may effectively improve the efficacy of radiotherapy for GBM patients, a potential new approach to the treatment of glioblastoma.
- Published
- 2023
- Full Text
- View/download PDF
32. Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages.
- Author
-
Yuan W, Zhang Q, Gu D, Lu C, Dixit D, Gimple RC, Gao Y, Gao J, Li D, Shan D, Hu L, Li L, Li Y, Ci S, You H, Yan L, Chen K, Zhao N, Xu C, Lan J, Liu D, Zhang J, Shi Z, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F, Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Mack SC, Zhang N, You Y, Rich JN, Sun G, and Wang X
- Subjects
- Humans, Animals, Mice, Tumor-Associated Macrophages metabolism, Phosphatidylinositol 3-Kinases metabolism, Cell Line, Tumor, Neoplastic Stem Cells metabolism, Cell Proliferation, Tumor Microenvironment genetics, Glioblastoma pathology, Brain Neoplasms pathology
- Abstract
Purpose: The dynamic interplay between glioblastoma stem cells (GSC) and tumor-associated macrophages (TAM) sculpts the tumor immune microenvironment (TIME) and promotes malignant progression of glioblastoma (GBM). However, the mechanisms underlying this interaction are still incompletely understood. Here, we investigate the role of CXCL8 in the maintenance of the mesenchymal state of GSC populations and reprogramming the TIME to an immunosuppressive state., Experimental Design: We performed an integrative multi-omics analyses of RNA sequencing, GBM mRNA expression datasets, immune signatures, and epigenetic profiling to define the specific genes expressed in the mesenchymal GSC subsets. We then used patient-derived GSCs and a xenograft murine model to investigate the mechanisms of tumor-intrinsic and extrinsic factor to maintain the mesenchymal state of GSCs and induce TAM polarization., Results: We identified that CXCL8 was preferentially expressed and secreted by mesenchymal GSCs and activated PI3K/AKT and NF-κB signaling to maintain GSC proliferation, survival, and self-renewal through a cell-intrinsic mechanism. CXCL8 induced signaling through a CXCR2-JAK2/STAT3 axis in TAMs, which supported an M2-like TAM phenotype through a paracrine, cell-extrinsic pathway. Genetic- and small molecule-based inhibition of these dual complementary signaling cascades in GSCs and TAMs suppressed GBM tumor growth and prolonged survival of orthotopic xenograft-bearing mice., Conclusions: CXCL8 plays critical roles in maintaining the mesenchymal state of GSCs and M2-like TAM polarization in GBM, highlighting an interplay between cell-autonomous and cell-extrinsic mechanisms. Targeting CXCL8 and its downstream effectors may effectively improve GBM treatment., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
33. PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma.
- Author
-
Zhao M, Li Y, Lu C, Ding F, Xu M, Ge X, Li M, Wang Z, Yin J, Zhang J, Wang X, Ge Z, Xiao H, Xiao Y, Liu H, Liu W, Cao Y, Wang Q, You Y, Wang X, Yang K, Shi Z, and Qian X
- Subjects
- Humans, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha genetics, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha metabolism, Organelle Biogenesis, Mitochondria metabolism, Carrier Proteins metabolism, Transcription Factors genetics, Transcription Factors metabolism, Glioma genetics, Glioma radiotherapy, Glioma metabolism
- Abstract
Radiotherapy is a major component of standard-of-care treatment for gliomas, the most prevalent type of brain tumor. However, resistance to radiotherapy remains a major concern. Identification of mechanisms governing radioresistance in gliomas could reveal improved therapeutic strategies for treating patients. Here, we report that mitochondrial metabolic pathways are suppressed in radioresistant gliomas through integrated analyses of transcriptomic data from glioma specimens and cell lines. Decreased expression of peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α), the key regulator of mitochondrial biogenesis and metabolism, correlated with glioma recurrence and predicted poor prognosis and response to radiotherapy of patients with glioma. The subpopulation of glioma cells with low-mitochondrial-mass exhibited reduced expression of PGC1α and enhanced resistance to radiotherapy treatment. Mechanistically, PGC1α was phosphorylated at serine (S) 636 by DNA-dependent protein kinase in response to irradiation. Phosphorylation at S636 promoted the degradation of PGC1α by facilitating its binding to the E3 ligase RNF34. Restoring PGC1α activity with expression of PGC1α S636A, a phosphorylation-resistant mutant, or a small-molecule PGC1α activator ZLN005 increased radiosensitivity of resistant glioma cells by reactivating mitochondria-related reactive oxygen species production and inducing apoptotic effects both in vitro and in vivo. In summary, this study identified a self-protective mechanism in glioma cells in which radiotherapy-induced degradation of PGC1α and suppression of mitochondrial biogenesis play a central role. Targeted activation of PGC1α could help improve response to radiotherapy in patients with glioma., Significance: Glioma cells reduce mitochondrial biogenesis by promoting PGC1α degradation to promote resistance to radiotherapy, indicating potential therapeutic strategies to enhance radiosensitivity., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
34. β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages.
- Author
-
Li D, Zhang Q, Li L, Chen K, Yang J, Dixit D, Gimple RC, Ci S, Lu C, Hu L, Gao J, Shan D, Li Y, Zhang J, Shi Z, Gu D, Yuan W, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F, Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Shi Y, You Y, Zhang N, Rich JN, and Wang X
- Subjects
- Cell Line, Tumor, Ecosystem, Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Stem Cells pathology, TOR Serine-Threonine Kinases, Transforming Growth Factor beta1, Tumor-Associated Macrophages, Brain Neoplasms metabolism, Brain Neoplasms pathology, Glioblastoma metabolism, Glioblastoma pathology, Tumor Microenvironment, beta 2-Microglobulin metabolism
- Abstract
Glioblastoma (GBM) is a complex ecosystem that includes a heterogeneous tumor population and the tumor-immune microenvironment (TIME), prominently containing tumor-associated macrophages (TAM) and microglia. Here, we demonstrated that β2-microglobulin (B2M), a subunit of the class I major histocompatibility complex (MHC-I), promotes the maintenance of stem-like neoplastic populations and reprograms the TIME to an anti-inflammatory, tumor-promoting state. B2M activated PI3K/AKT/mTOR signaling by interacting with PIP5K1A in GBM stem cells (GSC) and promoting MYC-induced secretion of transforming growth factor-β1 (TGFβ1). Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFβ1 secretion activated paracrine SMAD and PI3K/AKT signaling in TAMs and promoted an M2-like macrophage phenotype. These findings reveal tumor-promoting functions of B2M and suggest that targeting B2M or its downstream axis may provide an effective approach for treating GBM., Significance: β2-microglobulin signaling in glioblastoma cells activates a PI3K/AKT/MYC/TGFβ1 axis that maintains stem cells and induces M2-like macrophage polarization, highlighting potential therapeutic strategies for targeting tumor cells and the immunosuppressive microenvironment in glioblastoma., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
35. SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis.
- Author
-
Li W, Soufiany I, Lyu X, Lu C, Wei Y, Shi Z, and You Y
- Abstract
Background: Mounting evidences have shown the importance of lncRNAs in carcinogenesis and cancer progression. LBX2-AS1 is identified as an oncogenic lncRNA that is abnormally expressed in gastric cancer and lung cancer samples. This study aims to explore the potential role of LBX2-AS1 in regulating proliferation and EMT in glioma, and the underlying mechanism. Methods: Relative levels of LBX2-AS1 in glioma samples and cell lines were detected by qRT-PCR and FISH. In vivo and in vitro regulatory effects of LBX2-AS1 on proliferation and EMT were examined in the xenograft glioma model and glioma cells. The interaction between SP1 and LBX2-AS1 was assessed by ChIP. Through bioinformatic analyses, dual-luciferase reporter assay, RIP and Western blot, the regulation of LBX2-AS1 and miR-491-5p on the target gene LIF was identified. Results: LBX2-AS1 was upregulated in glioma samples and cell lines, and its transcription was promoted by binding to the transcription factor SP1. As a lncRNA mainly distributed in the cytoplasm, LBX2-AS1 sponge miR-491-5p to further upregulate LIF. The subsequent activated LIF/STAT3 signaling was responsible for promoting proliferation and EMT in glioma. Conclusion: LBX2-AS1 is upregulated by SP1 in glioma, which promotes the progression of glioma by targeting the miR-491-5p/LIF axis. In view of this, LBX2-AS1 is suggested as a novel diagnostic biomarker and therapeutic target of glioma., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
36. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
- Author
-
Yin J, Ge X, Shi Z, Yu C, Lu C, Wei Y, Zeng A, Wang X, Yan W, Zhang J, and You Y
- Subjects
- Animals, Antineoplastic Agents, Alkylating pharmacology, Apoptosis, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Brain Neoplasms drug therapy, Brain Neoplasms metabolism, Brain Neoplasms pathology, Cell Proliferation, Gene Expression Regulation, Neoplastic, Glioblastoma metabolism, Glioblastoma pathology, Humans, Male, Mice, Mice, Nude, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Drug Resistance, Neoplasm, Extracellular Vesicles metabolism, Glioblastoma drug therapy, Hypoxia physiopathology, MicroRNAs genetics, Neoplastic Stem Cells pathology, Temozolomide pharmacology
- Abstract
Rationale: Glioma stem-like cells (GSCs) contribute to temozolomide (TMZ) resistance in gliomas, although the mechanisms have not been delineated. Methods: In vitro functional experiments (colony formation assay, flow cytometric analysis, TUNEL assay) were used to assess the ability of extracellular vesicles (EVs) from hypoxic GSCs to promote TMZ resistance in glioblastoma (GBM) cells. RNA sequencing and quantitative Reverse Transcription-PCR were employed to identify the functional miRNA in hypoxic EVs. Chromatin immunoprecipitation assays were performed to analyze the transcriptional regulation of miRNAs by HIF1α and STAT3. RIP and RNA pull-down assays were used to validate the hnRNPA2B1-mediated packaging of miRNA into EVs. The function of EV miR-30b-3p from hypoxic GSCs was verified by in vivo experiments and analysis of clinical samples. Results: Hypoxic GSC-derived EVs exerted a greater effect on GBM chemoresistance than those from normoxic GSCs. The miRNA profiling revealed that miR-30b-3p was significantly upregulated in the EVs from hypoxic GSCs. Further, HIF1α and STAT3 transcriptionally induced miR-30b-3p expression. RNA immunoprecipitation and RNA-pull down assays revealed that binding of miR-30b-3p with hnRNPA2B1 facilitated its transfer into EVs. EV-packaged miR-30b-3p (EV-miR-30b-3p) directly targeted RHOB, resulting in decreased apoptosis and increased proliferation in vitro and in vivo . Our results provided evidence that miR-30b-3p in CSF could be a potential biomarker predicting resistance to TMZ. Conclusion: Our findings indicated that targeting EV-miR-30b-3p could provide a potential treatment strategy for GBM., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
37. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
- Author
-
Yin J, Zeng A, Zhang Z, Shi Z, Yan W, and You Y
- Subjects
- Animals, Apoptosis drug effects, Apoptosis genetics, Biological Transport, Biomarkers, Tumor, Cell Line, Tumor, Cell Survival drug effects, Cell Survival genetics, Circulating MicroRNA, Drug Resistance, Neoplasm genetics, ErbB Receptors metabolism, Flow Cytometry, Genes, Reporter, Humans, Male, Mice, MicroRNAs metabolism, RNA Interference, Signal Transduction, Brain Neoplasms genetics, Brain Neoplasms metabolism, Exosomes metabolism, Glioblastoma genetics, Glioblastoma metabolism, MicroRNAs genetics, Temozolomide pharmacology
- Abstract
Background: Although temozolomide (TMZ) resistance is a significant clinical problem in glioblastoma (GBM), its underlying molecular mechanisms are poorly understood. In this study, we identified the role of exosomal microRNAs (miRNAs) from TMZ-resistant cells as important mediators of chemoresistance in GBM cells., Methods: Exosomes were isolated from TMZ-resistant GBM cells and characterized via scanning electron microscopy (SEM). Expression levels of miR-1238 in GBM cell lines and their exosomes, clinical tissues, and sera were evaluated by RT-qPCR. In vitro and in vivo experiments were performed to elucidate the function of exosomal miR-1238 in TMZ resistance in GBM cells. Co-immunoprecipitation assays and western blot analysis were used to investigate the potential mechanisms of miR-1238/CAV1 that contribute to TMZ resistance., Findings: MiR-1238 levels were higher in TMZ-resistant GBM cells and their exosomes than in sensitive cells. Higher levels of miR-1238 were found in the sera of GBM patients than in healthy people. The loss of miR-1238 may sensitize resistant GBM cells by directly targeting the CAV1/EGFR pathway. Furthermore, bioactive miR-1238 may be incorporated into the exosomes shed by TMZ-resistant cells and taken up by TMZ-sensitive cells, thus disseminating TMZ resistance., Interpretation: Our findings establish that miR-1238 plays an important role in mediating the acquired chemoresistance of GBM and that exosomal miR-1238 may confer chemoresistance in the tumour microenvironment. These results suggest that circulating miR-1238 serves as a clinical biomarker and a promising therapeutic target for TMZ resistance in GBM. FUND: This study was supported by the National Natural Science Foundation of China (No·81402056, 81472362, and 81772951) and the National High Technology Research and Development Program of China (863) (No·2012AA02A508)., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
38. Role and mechanism of miR-222 in arsenic-transformed cells for inducing tumor growth.
- Author
-
Wang M, Ge X, Zheng J, Li D, Liu X, Wang L, Jiang C, Shi Z, Qin L, Liu J, Yang H, Liu LZ, He J, Zhen L, and Jiang BH
- Subjects
- Animals, Apoptosis drug effects, Arsenic Poisoning pathology, Cell Line, Transformed, Cell Line, Tumor, Cell Proliferation drug effects, Human Umbilical Vein Endothelial Cells, Humans, Lung Neoplasms metabolism, Lung Neoplasms pathology, Mice, Mice, Inbred BALB C, Mice, Nude, MicroRNAs antagonists & inhibitors, MicroRNAs biosynthesis, PTEN Phosphohydrolase genetics, Respiratory Mucosa drug effects, Respiratory Mucosa pathology, Up-Regulation, Arsenic toxicity, Cell Transformation, Neoplastic chemically induced, Lung Neoplasms chemically induced, MicroRNAs metabolism, PTEN Phosphohydrolase metabolism
- Abstract
High levels of arsenic in drinking water, soil, and air are associated with the higher incidences of several kinds of cancers worldwide, but the mechanism is yet to be fully discovered. Recently, a number of evidences show that dysregulation of microRNAs (miRNAs) induces carcinogenesis. In this study, we found miR-222 was upregulated in arsenic-transformed human lung epithelial BEAS-2B cells (As-T cells). Anti-miR-222 inhibitor treatment decreased cell proliferation, migration, tube formation, and induced apoptosis. In addition, anti-miR-222 inhibitor expression decreased tumor growth in vivo. We also found that inhibition of miR-222 induced the expression of its direct targets ARID1A and phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and activated apoptosis of As-T cells in part through ARID1A downregulation. These results indicate that miR-222 plays an important role in arsenic-induced tumor growth.
- Published
- 2016
- Full Text
- View/download PDF
39. GSK-3β regulates tumor growth and angiogenesis in human glioma cells.
- Author
-
Zhao P, Li Q, Shi Z, Li C, Wang L, Liu X, Jiang C, Qian X, You Y, Liu N, Liu LZ, Ding L, and Jiang BH
- Subjects
- Animals, Blotting, Western, Brain Neoplasms blood supply, Brain Neoplasms genetics, Brain Neoplasms pathology, Cell Line, Tumor, Disease Progression, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Glioma blood supply, Glioma genetics, Glioma pathology, Glycogen Synthase Kinase 3 genetics, Glycogen Synthase Kinase 3 beta, Humans, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Male, Mice, Inbred BALB C, Mice, Nude, Phosphorylation, Ribosomal Protein S6 Kinases, 70-kDa metabolism, Signal Transduction, TOR Serine-Threonine Kinases metabolism, Tissue Array Analysis, Transfection, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, beta Catenin genetics, beta Catenin metabolism, Brain Neoplasms enzymology, Cell Proliferation, Glioma enzymology, Glycogen Synthase Kinase 3 metabolism, Neovascularization, Pathologic
- Abstract
Background: Glioma accounts for the majority of primary malignant brain tumors in adults., Methods: Glioma specimens and normal brain tissues were analyzed for the expression levels of GSK-3β and p-GSK-3β (Ser9) by tissue microarray analysis (TMA) and Western blotting. Glioma cells over-expressing GSK-3β were used to analyze biological functions both in vitro and in vivo., Results: The levels of p-GSK-3β (Ser9), but not total GSK-3β, are significantly up-regulated in glioma tissues compared to normal tissues, and are significantly correlated with the glioma grades. Ectopic expression of GSK-3β decreased the phosphorylation levels of mTOR and p70S6K1; and inhibited β-catenin, HIF-1α and VEGF expression. Forced expression of GSK-3β in glioma cells significantly inhibited both tumor growth and angiogenesis in vivo., Conclusions: These results reveal that GSK-3β regulates mTOR/p70S6K1 signaling pathway and inhibits glioma progression in vivo; its inactivation via p-GSK-3β (Ser9) is associated with glioma development, which is new mechanism that may be helpful in developing GSK-3β-based treatment of glioma in the future.
- Published
- 2015
- Full Text
- View/download PDF
40. Association between survivin -31G > C promoter polymorphism and cancer risk: a meta-analysis.
- Author
-
Wang X, Huang L, Xu Y, Shi Z, Wang Y, Zhang J, Wang X, Cao L, Luo H, Chen J, Liu N, Yin Y, and You Y
- Subjects
- Alleles, Asian People genetics, Case-Control Studies, Confidence Intervals, Ethnicity genetics, Gene Frequency, Genetic Heterogeneity, Genotype, Humans, Neoplasms ethnology, Odds Ratio, Risk Factors, Sensitivity and Specificity, Survivin, Inhibitor of Apoptosis Proteins genetics, Neoplasms genetics, Polymorphism, Genetic, Promoter Regions, Genetic
- Abstract
Survivin is an inhibitor of apoptosis protein and has a crucial role in the development of cancer. The survivin -31G>C (rs9904341) promoter polymorphism influences survivin expression and has been implicated in cancer risk. However, conflicting results have been published from studies on the association between survivin -31G>C polymorphism and the risk of cancer. To clarify the role of this polymorphism in cancer, we performed a meta-analysis of all available and relevant published studies, involving a total of 3485 cancer patients and 3964 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results indicated that the variant genotypes were associated with a significantly increased cancer risk (CC vs GG: OR=1.58, 95% CI=1.20-2.10; CC/GC vs GG: OR=1.23, 95% CI=1.00-1.51; CC vs GG/GC: OR=1.51, 95% CI=1.23-1.85). In the stratified analyses, significantly increased risk was associated with the Asian populations (CC vs GG: OR=1.67, 95% CI=1.16-2.40; CC vs GG/GC: OR=1.50, 95% CI=1.17-1.91). We also performed the analyses by cancer type, and no statistical association was observed. The results suggest that the survivin -31G>C promoter polymorphism might be associated with an increased risk of cancer, especially in the Asian populations.
- Published
- 2012
- Full Text
- View/download PDF
41. Oral administration of apigenin inhibits metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian tumor model.
- Author
-
He J, Xu Q, Wang M, Li C, Qian X, Shi Z, Liu LZ, and Jiang BH
- Subjects
- Administration, Oral, Animals, Cell Line, Tumor, Female, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasms, Experimental metabolism, Neoplasms, Experimental pathology, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Apigenin pharmacology, Matrix Metalloproteinase 9 metabolism, Neoplasms, Experimental drug therapy, Ovarian Neoplasms drug therapy, Proto-Oncogene Proteins c-akt metabolism, Ribosomal Protein S6 Kinases, 70-kDa metabolism, Signal Transduction drug effects
- Abstract
Apigenin, a flavonoid commonly present in the daily diet, is known for its potential anti-tumor properties. However, the effect of apigenin via oral administration on tumor growth and metastasis remains unknown. In this study we developed an orthotopic ovarian tumor model in nude mice to test the effect of apigenin oral administration, and showed that apigenin inhibited the micrometastasis of cancer cells in the animal tumor model. To understand the mechanism of apigenin in inhibiting metastasis, we found that apigenin greatly inhibited MMP-9 expression and p-AKT and p-p70S6K1 levels in the tumor tissues compared to the control group. We further demonstrated that the downregulation of MMP-9 by apigenin was mediated by the AKT/p70S6K1 pathway. These findings help to address the question with common interests to the public of whether oral uptake of flavonoids is effective in preventing cancer. Our results demonstrate for the first time that oral uptake of apigenin can inhibit tumor metastasis through MMP-9 expression using the orthotopic ovarian tumor model.
- Published
- 2012
- Full Text
- View/download PDF
42. Updated meta-analysis of NFkappaB1 -94ins/Delattg promoter polymorphism and cancer risk based on 19 case-control studies.
- Author
-
Wang X, Lu P, Xu L, Xu Y, Shi Z, Xu J, Wang Y, Zhang J, Wang X, Cao L, Liu N, Yin Y, and You Y
- Subjects
- Case-Control Studies, Gene Frequency, Genotype, Humans, INDEL Mutation, Polymorphism, Single Nucleotide, Risk Factors, Genetic Predisposition to Disease, NF-kappa B genetics, Neoplasms genetics, Promoter Regions, Genetic genetics
- Abstract
Objective: Recently, a common insertion/deletion (-94insertion/deletion ATTG, rs28362491) polymorphism in the NFkappaB1 promoter region has been extensively investigated for association with cancer risk but the results have been inconsistent. In order to clarify the effect of the promoter polymorphism we performed an update meta-analysis of published case-control studies to better compare the results between studies., Methods: Relevant studies were identified via a thorough literature search on Medline and Embase database (up to August 10, 2011). The odds ratio (OR) and 95% confidence interval (95%CI) were used to investigate the strength of the association., Results: A total of 5,196 cases and 6,614 controls in 19 case-control studies from 16 publications were included in this meta-analysis. Overall, the variant genotypes were associated with a moderately decreased risk of all cancer types (OR =0.74, 95%CI =0.57-0.97 for DD versus II; OR =0.79, 95%CI =0.66-0.95 for DD versus II/ID). In the stratified analyses, significantly decreased risk was found among Asians (OR =0.52, 95%CI =0.42-0.65 for DD versus II; OR =0.74, 95%CI =0.66-0.83 for ID versus II; OR =0.64, 95%CI =0.53-0.78 for DD versus II/ID; OR =0.68, 95%CI =0.61-0.75 for DD/ID versus II). The validity of this association was further strengthened by the sensitivity analysis. No publication bias was observed in this study., Conclusions: Our results suggested that the -94deletion ATTG promoter polymorphism in NFkappaB1 gene might be associated with a decreased cancer risk, especially for Asian population.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.